{"filing":{"accession_number":"0001193125-26-384360","cik":"0001826457","ticker":"GLUE","company_name":"Monte Rosa Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"glue-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/glue-20260908.htm"},"events":[{"id":31764,"run_id":29164,"accession_number":"0001193125-26-384360","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Monte Rosa announced that its collaborator Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment and eligibility for up to $2.1 billion in additional development, regulatory, and sales milestones under their global exclusive license agreement. This represents a material operational and strategic milestone validating the company's technology platform and demonstrating significant progress in its partnered pipeline.","company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34744,"accession_number":"0001193125-26-384360","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Monte Rosa announced that its collaborator Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment and eligibility for up to $2.1 billion in additional development, regulatory, and sales milestones under their global exclusive license agreement. This is a material operational and strategic milestone in the development of a key partnered program, reflecting significant progress in the company's pipeline and validating its technology platform, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:04:50.586652+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34745,"accession_number":"0001193125-26-384360","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Monte Rosa announced that its collaborator Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment from Novartis. This represents a material operational and clinical development milestone under the existing global exclusive license agreement. While the payment itself is financial, the core event is the achievement of a clinical development milestone (Phase 2 initiation) that validates the program's progress and unlocks future milestone opportunities (up to $2.1 billion total). This is best classified as an operational milestone rather than a routine financial event, as it reflects meaningful progress in the company's partnered pipeline and demonstrates validation of its therapeutic approach.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:04:50.586652+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34744,"accession_number":"0001193125-26-384360","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Monte Rosa announced that its collaborator Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment and eligibility for up to $2.1 billion in additional development, regulatory, and sales milestones under their global exclusive license agreement. This is a material operational and strategic milestone in the development of a key partnered program, reflecting significant progress in the company's pipeline and validating its technology platform, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:04:50.586652+00:00","company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","filing_date":"2026-09-08"},{"id":34745,"accession_number":"0001193125-26-384360","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Monte Rosa announced that its collaborator Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment from Novartis. This represents a material operational and clinical development milestone under the existing global exclusive license agreement. While the payment itself is financial, the core event is the achievement of a clinical development milestone (Phase 2 initiation) that validates the program's progress and unlocks future milestone opportunities (up to $2.1 billion total). This is best classified as an operational milestone rather than a routine financial event, as it reflects meaningful progress in the company's partnered pipeline and demonstrates validation of its therapeutic approach.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:04:50.586652+00:00","company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","filing_date":"2026-09-08"}]}